Recurrent Endometrioid Adenocarcinoma of Endometrium With Bone Metastases

Oral nano-formulations for endocrine therapy of endometrioid adenocarcinomas

Endometrial cancer is one of the three major malignant tumors of the reproductive system that threaten women's lives and health. The incidence of this disease is on the rise globally. Most cases of endometrial cancer comprise endometrioid adenocarcinomas, whose treatment is challenged by factors such as their high recurrence rate and the need to preserve fertility among young patients. Thus, oral endocrine therapy has become the main treatment modality. The main drugs used in oral endocrine therapy are progestins, selective estrogen receptor antagonists, and aromatase inhibitors. However, their clinical use is hindered by their low solubility and low oral utilization. The rapid development of nanotechnology allows the combination of these drugs with oral nano-formulations to create a good carrier. Such nanocarriers, including nanospheres, nanocapsules, and micelles can protect the drug against clearance and increase the site specificity of drug delivery. This paper reviews the pathogenesis of endometrioid endometrial cancer (EEC) and oral nano-formulations for endocrine therapy.

Endometrial cancer recurrence in the sacrum and the Psoas: A case report and literature review

•

Our study describes an isolated recurrence in the sacrum and iliopsoas muscle.

•

Chemotherapy followed by definitive radiation can be an effective treatment plan.

•

Our case may closely resemble the Malignant Psoas Syndrome.

Musculoskeletal metastasis of endometrial carcinoma is rare. Data regarding the management of metastatic disease to these sites is limited. We report a case of a 73-year-old woman who had surgery for endometrial adenocarcinoma (FIGO stage IB, Grade II) followed by vaginal cuff brachytherapy and one year later developed an isolated recurrence in the sacrum and iliopsoas muscle. She was treated with chemotherapy followed by whole pelvis radiation and a complete clinical response was achieved. At her last follow up, 12 months after the completion of the radiation, she had no clinical or radiologic evidence of disease.

Adrenal and Bone Metastases as the Initial Presentation of Endometrial Carcinoma Diagnosed by 18F-FDG PET/CT

Adrenal and bone metastases as the initial presentation of endometrial carcinoma are rare. We report a case of endometrial carcinoma in a 47-year-old woman with initial manifestation as right chest wall pain, which was suspected as adrenal cortical carcinoma with rib metastasis after diagnostic CT scan. However, uterine and pelvic bone lesions were revealed by staging FDG PET/CT. Eventually, endometrial carcinoma with adrenal and bone metastases was confirmed pathologically.